Categories AlphaGraphs, Earnings, Health Care
DGX Infographic: Highlights of Quest Diagnostics’ Q4 2022 earnings
Quest Diagnostics Incorporated (NYSE: DGX) has announced financial results for the fourth quarter of 2022, reporting a sharp decline in adjusted profit and revenues.
On an adjusted basis, the healthcare company reported a net income of $1.98 per share for the December quarter, which is down 41% from the year-ago period. Unadjusted profit fell sharply to $101 million or $0.87 per share.
The bottom line was negatively impacted by a 15% decrease in revenues to $2.33 billion. The management expects full-year 2023 earnings to be between $7.61 per share and $8.21 per share.
“Quest had another strong year in 2022, with base business revenues growing more than 6% in the fourth quarter, and 5% for the full year. COVID-19 testing revenues declined as expected but still exceeded $1.4 billion in 2022,” said Quest’s CEO Jim Davis.
Most Popular
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel
TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic chimeric antigen receptor (CAR) T-cell therapy products for
Cintas Corp. (CTAS) Q3 2023 earnings and revenue increase
Uniform rental company Cintas Corporation (NASDAQ: CTAS) on Wednesday announced financial results for the third quarter of 2023, reporting higher earnings and revenues. At $2.19 billion, third-quarter revenues were up
Infographic: Micron (MU) reports net loss for Q2; revenue down 53%
Micron Technology Inc. (NASDAQ: MU) slipped to a loss in the second quarter of 2023 from a profit last year, hurt by a sharp fall in revenues. The chipmaker reported
